Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

N7161

Sigma-Aldrich

Nogo-66(1-40) antagonist peptide

≥84% (HPLC)

Synonym(s):

NEP (1-40)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C204H322N56O64 · xC2HF3O2
Molecular Weight:
4583.08 (free base basis)
MDL number:
MFCD06411437
UNSPSC Code:
12352202
NACRES:
NA.32

Quality Level

100

Assay

≥84% (HPLC)

form

lyophilized solid

color

white

solubility

H2O: 1 mg/mL

UniProt accession no.

Q9NQC3

storage temp.

−20°C

SMILES string

[nH]1cnc(c1)C[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CCCNC(=N)N)[C@H](CC)C)Cc6ccc(cc6

InChI

1S/C206H324N56O65/c1-23-104(15)163(258-169(292)109(20)226-174(297)126(59-67-148(210)272)240-201(324)166(107(18)26-4)261-199(322)160(101(9)10)255-153(277)92-223-171(294)120(41-30-33-75-207)230-186(309)138(86-115-51-57-119(271)58-52-115)249-202(325)165(106(

InChI key

OLEKMOOQFWTQGD-SJQNMCRDSA-N

Gene Information

human ... RTN4(57142)

Amino Acid Sequence

Arg-Ile-Tyr-Lys-Gly-Val-Ile-Gln-Ala-Ile-Gln-Lys-Ser-Asp-Glu-Gly-His-Pro-Phe-Arg-Ala-Tyr-Leu-Glu-Ser-Glu-Val-Ala-Ile-Ser-Glu-Glu-Leu-Val-Gln-Lys-Tyr-Ser-Asn-Ser-NH2

Application

Nogo-66(1-40) antagonist peptide has been used as a Nogo-66 receptor antagonist peptide:
  • to study the preliminary therapeutic effect after inhibition of Nogo-A in the cauda equina compression (CEC) model
  • to determine the effects of Nogo-A/NgR1 on autophagic activation
  • to study its role in Nogo-B mediated axonal branching using Schwann cells and sensory neurons of mice

Biochem/physiol Actions

Myelin-derived axon outgrowth inhibitors, such as Nogo, may account for the lack of axonal regeneration in the central nervous system (CNS) after trauma in adult mammals. Nogo-66 can inhibit axonal outgrowth through an axonal Nogo-66 receptor (NgR). Competitive antagonists of NgR derived from amino-terminal peptide fragments of Nogo-66. The Nogo-66(1 40) antagonist peptide (NEP1 40) blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro, demonstrating that NgR mediates a significant portion of axonal outgrowth inhibition by myelin. Intrathecal administration of NEP1 40 to rats with mid-thoracic spinal cord hemisection results in significant axon growth of the corticospinal tract, and improves functional recovery. Thus, Nogo-66 and NgR have central roles in limiting axonal regeneration after CNS injury, and NEP1-40 provides a potential therapeutic agent.
Nogo-66(1-40) promotes axonal regeneration; it blocks effects of axon outgrowth inhibitors such as Nogo66.

Legal Information

Sold under a non-exclusive license. For research use only, and not for diagnostic or therapeutic use or for use in humans.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

N7161-BULK:
N7161-1MG:
N7161-VAR:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
064M4720V
033M4716V
076K4702
123K1335

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wei Xu et al.
Neuroscience, 431, 103-114 (2020-02-19)
Focal cerebral infarction leads to autophagic activation, which contributes to secondary neuronal damage in the ipsilateral thalamus. Although Nogo-A deactivation enhances neuronal plasticity, its role in autophagic activation in the thalamus after ischemic stroke remains unclear. This study aimed to
Tadzia GrandPré et al.
Nature, 417(6888), 547-551 (2002-05-31)
Myelin-derived axon outgrowth inhibitors, such as Nogo, may account for the lack of axonal regeneration in the central nervous system (CNS) after trauma in adult mammals. A 66-residue domain of Nogo (Nogo-66) is expressed on the surface of oligodendrocytes and
Neutralization of Nogo-A enhances synaptic plasticity in the rodent motor cortex and improves motor learning in vivo.
Zemmar A, Weinmann O, Kellner Y, et al.
The Journal of Neuroscience, 34(26), 8685-8698 (2014)
Xiaofei Sun et al.
Biochemical and biophysical research communications, 527(1), 131-137 (2020-05-25)
To investigate the expression of Nogo-A in dorsal root ganglion (DRG) in rats with cauda equina injury and the therapeutic effects of blocking Nogo-A and its receptor. Fifty-eight male Sprague-Dawley rats were divided randomly into either the sham operation group
Peng Zhai et al.
Biomedical materials (Bristol, England), 10(4), 045016-045016 (2015-08-05)
The adult mammalian central nervous system has limited ability to regenerate after injury. This is due, in part, to the presence of myelin-associated axon growth inhibitory proteins such as Nogo-A that bind and activate the Nogo receptor, leading to profound

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service